

Quizartinib **Catalog No: tcsc0211**

Available Sizes

ize: 5mg	
ize: 10mg	
ize: 50mg	
ize: 100mg	
ize: 200mg	
ize: 500mg	
ize: 1g	
ize: ² g	
ize: 5g	
Specifications	

CAS No:

950769-58-1

Formula:

 $C_{29}H_{32}N_6O_4S$

Pathway: Protein Tyrosine Kinase/RTK;Autophagy

Target:

FLT3;Autophagy

Purity / Grade:

>98%

Copyright 2021 Taiclone Biotech Corp.



Solubility:

DMSO : ≥ 33 mg/mL (58.86 mM)

Alternative Names:

AC220

Observed Molecular Weight:

560.67

Product Description

Quizartinib is a uniquely potent and selective **FIt3** inhibitor with K_d (FLT3 binding affinity) of 1.6±0.7 nM in Biochemical assay.


IC50 & Target: Kd: 1.6±0.7 nM (Flt3)^[1]

In Vitro: Quizartinib (AC220) is a novel compound expressly optimized as a FLT3 inhibitor for the treatment of acute myeloid leukemia (AML). Quizartinib inhibits FLT3-WT and FLT3-ITD autophosphorylation with IC_{50} of 4.2±0.3 nM and 1.1±0.1 nM, respectively. Quizartinib inhibits MV4-11 and A375 cells with IC_{50} of 0.56±0.3 nM and >10 000 nM, respectively. Quizartinib inhibits FLT3 with low nanomolar potency in cellular assays and is highly selective when screened against the majority of the human protein kinome^[1].

In Vivo: Quizartinib (AC220) inhibits FLT3 activity in vivo, significantly extends survival in a mouse model of FLT3-ITD AML at doses as low as 1 mg/kg when dosed orally once a day, eradicates tumors in a FLT3-dependent mouse xenograft model at 10 mg/kg, and potently inhibits FLT3 activity in primary patient cells. The oral bioavailability of Quizartinib, determined in rats by comparing oral and intravenous pharmacokinetics at 3 mg/kg, is approximately 40%. A single 10 mg/kg dose of Quizartinib is administered by oral gavage, and mice are killed at 2 time points after dosing, using groups of 4 animals each. Quantitation of total FLT3 and phospho-FLT3 in tumor samples revealed time-dependent inhibition of FLT3 autophosphorylation. FLT3 activity is inhibited by 90% at 2 hours, and 40% at 24 hours after administration. The extent of inhibition therefore correlated well with the expected free Quizartinib plasma levels, based on pharmacokinetic experiments^[1].

Copyright 2021 Taiclone Biotech Corp.





All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.